Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that despite a relatively limited diagnosed prevalent population, the Crohn's disease drug market will experience steady growth. According to the new Pharmacor report entitled Crohn's Disease, this growth will be fueled by the increased use of current and emerging high-priced biologics.

Increased uptake of the high-priced tumor necrosis factor-alpha (TNF- alpha) inhibitor infliximab (Centocor [a Johnson & Johnson subsidiary] /Schering-Plough/Tanabe Seiyaku's Remicade) -- the only biological agent currently approved for the treatment of Crohn's disease -- will help drive sales growth in the next five years. However, the launch and subsequent uptake of high-priced emerging biological agents, including two novel TNF-alpha inhibitors, will be the main driver of growth in the Crohn's disease market during the next ten years.

"These novel products will provide more treatment options for patients whose disease is unresponsive to less expensive, conventional Crohn's therapies (i.e., aminosalicylates, immunosuppressants, and corticosteroids) and for patients who fail infliximab," said Daphne Monie, Ph.D., analyst at Decision Resources, Inc. "Although the patient share for biologics will reach only an estimated 16% by 2014, their high prices will help drive total sales for these agents to approximately $1.3 billion in 2014-73% of the overall 2014 Crohn's disease market."

About Crohn's Disease

Crohn's disease is a chronic, relapsing/remitting inflammatory disease of the gastrointestinal (GI) tract. The regions of the GI tract most often affected by Crohn's disease are the small intestine and the large intestine, or colon, including the rectum. Common symptoms of Crohn's include diarrhea, abdominal pain, rectal bleeding, weight loss, and complications such as intestinal abscesses, fistulas, and intestinal obstructions.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Defying National Trends, HMOs Remain Popular in Massachusetts, According to HealthLeaders-InterStudy

View Now